Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Accendra Health, Inc.NYSE: ACH

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $382.61M fell 81.8% year over year, behind the -67.6% change in trailing-twelve-month cost of revenue. Sequentially, it fell 8.6% from the prior quarter. Over 3 fiscal years it compounded at -42.3% a year.

Context

  • Cost of revenue amounted to 56.5% of revenue in FY2025, down 22.8 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -81.8% toward the trailing-twelve-month pace of -67.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$382.61M-8.6% QoQ
Last fiscal yearDec 2025
$1.56B-81.6% YoY
LTMMar 2026
$1.59B-67.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-81.8%——
1 year-81.6%——
3-year CAGR-42.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
1.56B USD
Year-over-year change
-81.6%
4-year CAGR
-34.1%

Cost of Revenue vs competitors

How ACH compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -67.6% is the 8th highest of 9, against a peer median of -3.6%.
  • Cost of revenue amounts to 58.7% of revenue for ACH, versus a peer median of 41.5%.
ACH Competitors
Cost of Revenue for ACH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACHAccendra Health, Inc.LTM Mar 2026$1.59B USD-67.6%-42.3%58.7%
HITIHigh Tide Inc.LTM Apr 2026CA$553.94M CAD+35.7%+19.8%82.5%
CGCCanopy Growth CorporationLTM Mar 2026CA$234.68M CAD+23.9%-0.9%75.1%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$77.25M USD-23.8%-4.7%—
OMOutset Medical, Inc.LTM Mar 2026$69.8M USD-5.5%-9.3%59.4%
EDITEditas Medicine, Inc.LTM Mar 2026$36.44M USD-53.4%—94.2%
SGHTSight Sciences, Inc.LTM Mar 2026$11M USD-1.8%-4.7%13.8%
CVRXCVRx, Inc.LTM Mar 2026$8.55M USD-0.9%+18.5%14.5%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.98M USD-86.0%-44.1%23.7%
BIOABioAge Labs, Inc.LTM Mar 2026$63K USD——0.6%
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ACH) —-3.6%-4.7%41.5%

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.79B9.96B10.33B10.7B2.76B
Cost of Revenue8.27B8.13B8.21B8.48B1.56B
Gross Profit1.51B1.83B2.13B2.22B1.2B
Gross Margin15.5%18.3%20.6%20.7%43.5%
Research & Development12.1M0000
Selling, General & Admin1.08B1.55B1.81B1.91B1.05B
Operating Expenses1.14B1.68B2.02B2.43B1.05B
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
EBITDA415.47M368.45M390.57M51.22M364.68M
EBITDA Margin4.2%3.7%3.8%0.5%13.2%
Operating Income368.47M142.91M104.51M(207.77M)150.16M
Operating Margin3.8%1.4%1.0%-1.9%5.4%
Interest Income00000
Interest Expense48.09M128.89M157.92M143.8M129.2M
Other Income / Expenses(91.72M)(132.02M)(159.23M)(149.59M)(252.11M)
Income Before Tax276.75M10.89M(54.73M)(357.36M)(101.95M)
Pre-Tax Margin2.8%0.1%-0.5%-3.3%-3.7%
Income Tax Expense55.17M(11.5M)(13.43M)5.33M729K
Net Income221.59M22.39M(41.3M)(362.69M)(1.1B)
Net Margin2.3%0.2%-0.4%-3.4%-39.8%
EPS (Basic)3.050.30(0.54)(4.73)(14.31)
EPS (Diluted)2.940.29(0.54)(4.73)(14.31)
Weighted Avg Shares72.74M74.5M75.79M76.74M76.9M
Weighted Avg Shares (Diluted)75.49M76.22M75.79M76.74M76.9M

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.